Literature DB >> 20628002

Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation.

Wenxing Chen1, Yan Luo, Lei Liu, Hongyu Zhou, Baoshan Xu, Xiuzhen Han, Tao Shen, Zhijun Liu, Yin Lu, Shile Huang.   

Abstract

Cryptotanshinone (CPT), a natural compound isolated from the plant Salvia miltiorrhiza Bunge, is a potential anticancer agent. However, little is known about its anticancer mechanism. Here, we show that CPT inhibited cancer cell proliferation by arresting cells in G(1)-G(0) phase of the cell cycle. This is associated with the inhibition of cyclin D1 expression and retinoblastoma (Rb) protein phosphorylation. Furthermore, we found that CPT inhibited the signaling pathway of the mammalian target of rapamycin (mTOR), a central regulator of cell proliferation. This is evidenced by the findings that CPT inhibited type I insulin-like growth factor I- or 10% fetal bovine serum-stimulated phosphorylation of mTOR, p70 S6 kinase 1, and eukaryotic initiation factor 4E binding protein 1 in a concentration- and time-dependent manner. Expression of constitutively active mTOR conferred resistance to CPT inhibition of cyclin D1 expression and Rb phosphorylation, as well as cell growth. The results suggest that CPT is a novel antiproliferative agent. 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628002      PMCID: PMC2917475          DOI: 10.1158/1940-6207.CAPR-10-0020

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  56 in total

1.  GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Robert R Latek; Kalyani V P Guntur; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

2.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

3.  The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G1-prolongation of NIH3T3 cells.

Authors:  Y Chen; E S Knudsen; J Y Wang
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

4.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

Authors:  Robbie Loewith; Estela Jacinto; Stephan Wullschleger; Anja Lorberg; José L Crespo; Débora Bonenfant; Wolfgang Oppliger; Paul Jenoe; Michael N Hall
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

5.  Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.

Authors:  Marina K Holz; John Blenis
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

6.  Treatment of chronic liver diseases with traditional Chinese medicine.

Authors:  B E Wang
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

7.  Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.

Authors:  J Nourse; E Firpo; W M Flanagan; S Coats; K Polyak; M H Lee; J Massague; G R Crabtree; J M Roberts
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

8.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

9.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Authors:  W B Isaacs; B S Carter; C M Ewing
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

10.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

View more
  41 in total

1.  Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).

Authors:  Wei Liu; Bing Yu; Gang Xu; Wei-Ren Xu; Mignon L Loh; Li-Da Tang; Cheng-Kui Qu
Journal:  J Med Chem       Date:  2013-09-04       Impact factor: 7.446

2.  Cryptotanshinone inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3/ERK and small GTPase pathways.

Authors:  Yan Luo; Wenxing Chen; Hongyu Zhou; Lei Liu; Tao Shen; J Steven Alexander; Shizhong Zheng; Yin Lu; Shile Huang
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

Review 3.  Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.

Authors:  Wenxing Chen; Yin Lu; Guangying Chen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

4.  Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function.

Authors:  Yanli Li; Yi Gong; Linglin Li; Hamid M Abdolmaleky; Jin-Rong Zhou
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

5.  Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E.

Authors:  Yuqing Ge; Rubin Cheng; Yuhong Zhou; Jianping Shen; Laijun Peng; Xiaofeng Xu; Qun Dai; Pei Liu; Haibing Wang; Xiaoqiong Ma; Jia Jia; Zhe Chen
Journal:  Mol Cell Biochem       Date:  2012-05-22       Impact factor: 3.396

6.  Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling.

Authors:  Liang Lu; Cuixian Li; Dong Li; Ying Wang; Chun Zhou; Weiwei Shao; Jin Peng; Yan You; Xinwen Zhang; Xiaoyan Shen
Journal:  Mol Cell Biochem       Date:  2013-06-06       Impact factor: 3.396

7.  Cryptotanshinone activates p38/JNK and inhibits Erk1/2 leading to caspase-independent cell death in tumor cells.

Authors:  Wenxing Chen; Lei Liu; Yan Luo; Yoshinobu Odaka; Sanket Awate; Hongyu Zhou; Tao Shen; Shizhong Zheng; Yin Lu; Shile Huang
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-03

8.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

9.  Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling.

Authors:  Shanhu Li; Hongtao Wang; Liu Hong; Wei Liu; Fang Huang; Jian Wang; Peng Wang; Xiaoqing Zhang; Jianguang Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  Inhibitory effect of cryptotanshinone on angiogenesis and Wnt/β-catenin signaling pathway in human umbilical vein endothelial cells.

Authors:  Qian Chen; Qin Zhuang; Wei Mao; Xiao-ming Xu; Li-hui Wang; Hai-bing Wang
Journal:  Chin J Integr Med       Date:  2014-04-16       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.